Neuro3d Receives Support from ANVAR for Ongoing Clinical Development of its Antidepressant
20-Jul-2004 -
Neuro3d, a biopharmaceutical company focused on drug discovery and development for psychiatric disorders, announced today that ANVAR, the French Agency for Innovation, has provided the company EUR900,000 funding to support further clinical development of the phosphodiesterase-4 inhibitor ND1251 ...
Alzheimer's disease
antidepressants
CNS disorders
+5